Iambic Therapeutics Plans Nasdaq IPO Above $800 Million Valuation

1 min read

The Nvidia- and AbbVie-backed life sciences company plans to list under the ticker IAM and leverages artificial intelligence.

By John Kim

Published Oct 8, 2026, 9:25 AM EDT

Iambic Therapeutics plans to list on Nasdaq under the ticker IAM at a valuation exceeding $800 million.

The Nvidia- and AbbVie-backed life sciences company uses artificial intelligence and described the proposed listing Thursday.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.